Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedolizumab Induction in Moderate to Severe Crohn's Disease (GEMINI III)
NCT01224171Phase 3Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Nov 2010
- Primary completion
- Feb 2012
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in Crohn's disease comparing Placebo with Vedolizumab (2 arms). Primary endpoint: Percentage of Participants in Clinical Remission in the TNF Antagonist Failure Subpopulation at 6 weeks. Started Nov 2010; status: completed.
02
Drugs
vedolizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT01224171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01224171.